Is USANA Health Sciences, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 16, an EV to EBITDA of 4.61, and a Price to Book Value of 1.03. In comparison, Chromadex Corp. has a P/E of 39.82 and Nature's Sunshine Products, Inc. shows a P/E of 21.11, both indicating that USANA's valuation is not justified relative to its peers.
The company's recent performance has been poor, with a year-to-date return of -42.74% compared to the S&P 500's 16.30%, and a staggering -73.15% return over the past five years against the S&P's 109.18%. This stark contrast reinforces the notion that USANA Health Sciences, Inc. is currently overvalued.